| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western
world. Current research is focusing on the urgent unmet need for agents that
improve survival. Improved responses from treatment regimens that combine
targeted biological agents with established chemotherapy, as well as increased
drug therapy for early-stage patients who are likely to progress based on
potential prognostic markers, have already begun and will continue to create
market opportunities and propel steady growth of the CLL market. In this
report, we provide an overview of CLL, including its staging, epidemiology,
and biological markers. We discuss the current treatments and promising
late-stage agents in development for CLL, as well as the market outlook though
2010.
TABLE OF CONTENTS
- Introduction
- Leukemia
- Characteristics
- Etiology and Pathophysiology
- Symptoms
- Staging and Survival
- Epidemiology
- Prognosis
- Options for Chronic Lymphocytic Leukemia
- Treatment
- Decisions
- Line Therapies
- Second-Line Therapies
- Therapies
- Emerging Therapies for Chronic Lymphocytic
- Leukemia
- Antibodies
- Rituximab
- Lumiliximab
- Other Monoclonal Antibodies
- Immunotoxins
- Inhibitors
- Antisense Oligonucleotides
- Outlook
- Table 1 Common Staging Systems Used in the Treatment of CLL
- Table 2 Select Current Therapies Used for the Treatment of CLL, 2006
- Table 3 NCI Definition of Response to Treatment in CLL Patients
- Table 4 Select Emerging Therapies for the Treatment of CLL in the United
States, 2006
- Figure 1 Treatment Algorithm for Chronic Lymphocytic Leukemia
|
